All reported clinical features were comparable between group 1 and 2 except concerning melanoma mutational status (68% of melanomas in patients in group 1 where BRAF, NRAS, cKIT wild type, while they were only 2.6% in group 2 (p < 0.001)), the type of CC (56.0% of dacarbazine in group 1 vs. 28.9% in group 2, p = 0.023), and the ECOG; which was significantly higher in group 1 (ECOG 3‐4 61.0% vs. 20.8%, p = 0.004). This evidence concerns the gene NRAS and melanoma.